HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
August 11, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
HB-200 Phase 1 data presented at ASCO met all endpoints in heavily pre-treated head and neck cancer patients; Phase 2 study underwayUS Food and Drug Administration accepted HOOKIPA’s Investigational...
HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022
August 04, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Aug. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...
FDA accepts HOOKIPA’s Investigational New Drug Application for HB-300 for the treatment of metastatic castration-resistant prostate cancer
July 25, 2022 08:00 ET
|
HOOKIPA Pharma Inc.
Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early 2023Drug Master File (DMF) accepted to support future FDA submissions ...
HOOKIPA Announces Executive Leadership Changes
June 21, 2022 09:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, June 21, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA to Participate in the JMP Securities Life Sciences Conference
June 09, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, June 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
June 05, 2022 09:00 ET
|
HOOKIPA Pharma Inc.
Alternating 2-vector therapy showed superior antigen-specific T cell responses, more robust anti-tumor activity and similar tolerability vs. single-vector therapyPhase 2 to proceed with alternating...
Preclinical Data on Novel Arenaviral HIV Therapeutic Vaccines Presented at Keystone Symposium
June 03, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
Oral and poster presentations highlight robust and high-quality immune responses following administration of novel arenaviral therapeutic vaccines in preclinical setting Alternating 2-vector...
HOOKIPA to Present Complete HB-200 Phase 1 Results and Recommended Phase 2 Dose for HB-202/HB-201 for the Treatment of Advanced HPV16+ Cancers at ASCO
May 26, 2022 17:15 ET
|
HOOKIPA Pharma Inc.
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and...
HOOKIPA Pharma Reports First Quarter 2022 Financial Results and Recent Highlights
May 16, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
HB-200 program on track to report Phase 1 data mid-year, Phase 2 data in combination with pembrolizumab in second half of 2022Q1 capital raise and Gilead collaboration funding generated a strong cash...
HOOKIPA Pharma to Report First Quarter 2022 Financial Results on May 16, 2022
May 09, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, May 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...